Attached files
| file | filename |
|---|---|
| S-1/A - S-1/A - S1 Biopharma, Inc. | a2222125zs-1a.htm |
| EX-4.6 - EX-4.6 - S1 Biopharma, Inc. | a2222125zex-4_6.htm |
| EX-3.1 - EX-3.1 - S1 Biopharma, Inc. | a2222125zex-3_1.htm |
| EX-4.4 - EX-4.4 - S1 Biopharma, Inc. | a2222125zex-4_4.htm |
| EX-3.2 - EX-3.2 - S1 Biopharma, Inc. | a2222125zex-3_2.htm |
| EX-4.3 - EX-4.3 - S1 Biopharma, Inc. | a2222125zex-4_3.htm |
| EX-1.1 - EX-1.1 - S1 Biopharma, Inc. | a2222125zex-1_1.htm |
| EX-4.2 - EX-4.2 - S1 Biopharma, Inc. | a2222125zex-4_2.htm |
| EX-4.5 - EX-4.5 - S1 Biopharma, Inc. | a2222125zex-4_5.htm |
| EX-5.1 - EX-5.1 - S1 Biopharma, Inc. | a2222125zex-5_1.htm |
QuickLinks -- Click here to rapidly navigate through this document
Consent of Independent Registered Public Accounting Firm
The
Board of Directors
S1 Biopharma, Inc.:
We consent to the use of our report included herein and to the reference to our firm under the heading "Experts" in the prospectus. Our report dated July 25, 2014, except as to Note 2(1), which is as of November 5, 2014, contains an explanatory paragraph that states that S1 Biopharma, Inc. has incurred recurring losses and negative cash flows from operations since inception and has an accumulated deficit at December 31, 2013 of $3.4 million which raises substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.
/s/ KPMG LLP
Philadelphia, Pennsylvania
November 26, 2014
Consent of Independent Registered Public Accounting Firm